-
Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma
Tue, May 26 2020
In an NCI study, an alternative treatment regimen called dose-adjusted EPOCH-R that is less toxic than standard dose-intensive chemotherapy was highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status.
-
Higher daily step count linked with lower all-cause mortality
Tue, Mar 24 2020
In a new study, higher daily step counts were associated with lower mortality risk from all causes. Researchers found that the number of steps taken each day, but not the intensity of the stepping, had a strong association with mortality.
-
NCI statement on clinical trials during COVID-19 pandemic
Thu, Mar 19 2020
Statement from the National Cancer Institute providing information regarding treatment of cancer patients and participation in clinical trials during the COVID-19 pandemic.
-
NCI study provides genetic insights into osteosarcoma in children
Thu, Mar 19 2020
A new study offers insight into genetic alterations associated with osteosarcoma, the most common bone tumor of children and adolescents, and the findings have implications for genetic testing of children with osteosarcoma and their families.
-
In NIH trial, selumetinib shrinks tumors, provides clinical benefit for children with NF1
Wed, Mar 18 2020
An NCI clinical trial finds the drug selumetinib improves outcomes for children with neurofibromatosis type 1 (NF1), shrinking inoperable tumors called plexiform neurofibromas, reducing pain, and improving function and overall quality of life.
